Quadruplet Regimens Boost Myeloma Response Depth
- Multiple myeloma is a cancer of plasma cells,a type of white blood cell.
- For elderly and non-transplant eligible patients, the treatment landscape has been particularly challenging.
- The paradigm in multiple myeloma treatment is shifting towards achieving the deepest possible response, rather than simply controlling the disease.
“`html
Anti-CD38 Quadruplet Regimens: Revolutionizing Treatment for Multiple Myeloma
Table of Contents
Understanding Multiple Myeloma and the Need for New therapies
Multiple myeloma is a cancer of plasma cells,a type of white blood cell. Its characterized by the uncontrolled proliferation of these cells in the bone marrow, leading to various complications including bone pain, anemia, kidney problems, and increased susceptibility to infections. Historically, treatment options were limited, but recent advances, particularly in the development of novel agents, have substantially improved patient outcomes.
For elderly and non-transplant eligible patients, the treatment landscape has been particularly challenging. These patients often have comorbidities that make them less suitable for aggressive therapies like stem cell transplantation. Therefore, there’s a critical need for effective and well-tolerated regimens that can deliver deep remissions.
The Rise of Anti-CD38 Quadruplet Regimens
The paradigm in multiple myeloma treatment is shifting towards achieving the deepest possible response, rather than simply controlling the disease. This shift is driven by the understanding that minimal residual disease (MRD) negativity – the absence of detectable cancer cells – correlates with improved progression-free survival and overall survival. Quadruplet regimens, incorporating an anti-CD38 antibody, are playing a key role in this evolution.
Anti-CD38 antibodies, such as isatuximab, target the CD38 protein found on the surface of myeloma cells. By binding to CD38, these antibodies trigger several mechanisms of action, including antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), leading to the destruction of myeloma cells.
The INNROAD Clinical Trial: A Landmark Study
The INNROAD clinical trial demonstrated the efficacy and safety of isatuximab in combination with VRD (bortezomib,lenalidomide,and dexamethasone) in non-transplant-eligible patients with multiple myeloma. The trial showed significant improvements in depth of response, with a higher proportion of patients achieving stringent complete remission (sCR) compared to VRD alone.
| Outcome | VRD Alone | VRD + is
|
|---|